CCP
TMO icon

Corient Capital Partners’s Thermo Fisher Scientific TMO Stock Holding History

Corient Capital Partners’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4.44M Hold
8,173
– – 0.33% 69
2022
Q2 		$4.44M Buy
8,173
+861
+12% +$474K 0.34% 73
2022
Q1 		$4.32M Buy
7,312
+304
+4% +$175K 0.29% 85
2021
Q4 		$4.68M Buy
7,008
+200
+3% +$125K 0.31% 81
2021
Q3 		$3.89M Buy
6,808
+368
+6% +$202K 0.28% 82
2021
Q2 		$3.25M Buy
6,440
+372
+6% +$176K 0.24% 90
2021
Q1 		$2.77M Buy
6,068
+217
+4% +$104K 0.24% 86
2020
Q4 		$2.73M Sell
5,851
-2,551
-30% -$1.2M 0.27% 83
2020
Q3 		$3.71M Sell
8,402
-138
-2% -$57K 0.43% 57
2020
Q2 		$3.09M Buy
8,540
+885
+12% +$297K 0.38% 65
2020
Q1 		$2.17M Buy
7,655
+1,063
+16% +$335K 0.34% 77
2019
Q4 		$2.14M Buy
6,592
+138
+2% +$41.8K 0.27% 82
2019
Q3 		$1.88M Buy
6,454
+988
+18% +$283K 0.27% 84
2019
Q2 		$1.61M Buy
5,466
+296
+6% +$81.5K 0.25% 102
2019
Q1 		$1.42M Buy
5,170
+2,074
+67% +$516K 0.23% 126
2018
Q4 		$693K Buy
3,096
+1,206
+64% +$283K 0.12% 181
2018
Q3 		$462K Hold
1,890
– – 0.08% 201
2018
Q2 		$392K Buy
1,890
+204
+12% +$43.3K 0.07% 207
2018
Q1 		$348K Buy
1,686
+28
+2% +$5.88K 0.06% 201
2017
Q4 		$315K Buy
1,658
+193
+13% +$37K 0.05% 228
2017
Q3 		$277K Sell
1,465
-23
-2% -$4.17K 0.05% 234
2017
Q2 		$260K Sell
1,488
-180
-11% -$30.2K 0.04% 271
2017
Q1 		$256K Sell
1,668
-154
-8% -$23.5K 0.04% 270
2016
Q4 		$257K Sell
1,822
-396
-18% -$58.4K 0.05% 272
2016
Q3 		$353K Buy
+2,218
New +$342K 0.07% 234

Other funds holding TMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Capital Partners's TMO Position: Q3 2022 in Review

Corient Capital Partners held its Thermo Fisher Scientific (TMO) position steady in Q3 2022 at 8,173 shares worth $4.44M. The position accounts for 0.33% of the portfolio, ranked #69.

Corient Capital Partners first reported a position in TMO in Q3 2016 and has held it in 25 quarters since. The position peaked at $4.68M in Q4 2021. 2,266 funds tracked by Wall St. Rank hold TMO as of Q3 2022.

  • Corient Capital Partners held 8,173 shares of Thermo Fisher Scientific worth $4.44M as of Q3 2022.
  • Corient Capital Partners left its Thermo Fisher Scientific share count unchanged in Q3 2022.
  • Thermo Fisher Scientific made up 0.33% of Corient Capital Partners's portfolio in Q3 2022, its #69 holding.
  • Corient Capital Partners first reported a position in Thermo Fisher Scientific in Q3 2016 and has held it in 25 quarters since.
  • Corient Capital Partners's Thermo Fisher Scientific position peaked at $4.68M in Q4 2021.
  • 2,266 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.